Table 1.
Dosimetric values and comparisons for proton and three-dimensional (3D) conformal plans
| IMPT TANG_EN | IMPT TANG_PA | pa | 3DCRT | pb | pc | PSPB | pd | pe | |
| PTV_eval | |||||||||
| V90 (%) | 98.40% (95.0–100) | 97.50% (95.0–99.0) | 10.001 | 96.90% (92.0–99.4) | 20.001 | 60.375 | 96.40% (92.0–99.2) | 30.001 | 40.059 |
| Clinical target volume | |||||||||
| V90 (%) | 99.60% (99.0–100) | 99.00% (96.0–100) | 10.003 | 99.50% (97.7–100) | 60.922 | 30.064 | 99.70% (98.0–100) | 50.625 | 20.017 |
| Ipsilateral normal breast | |||||||||
| V90 (%) | 9.70% (4.00–21.00) | 9.80% (4.00–23.00) | 60.966 | 19.40% (9.20–47.50) | 10.001 | 20.001 | 12.40% (7.00–26.80) | 30.001 | 40.001 |
| V75 (%) | 17.10% (8.00–33.00) | 19.10% (10.00–38.00) | 50.010 | 30.00% (21.40–58.70) | 10.001 | 20.001 | 19.30% (10.90–36.40) | 40.007 | 60.296 |
| V50 (%) | 28.00% (12.00–48.00) | 30.50% (17.00–57.00) | 50.006 | 43.50% (28.60–68.80) | 10.001 | 20.001 | 26.90% (13.80–47.80) | 60.577 | 40.002 |
| V20 (%) | 41.90% (20.00–65.00) | 44.30% (27.00–69.00) | 50.054 | 60.20% (39.10–86.00) | 10.001 | 20.001 | 38.80% (26.50–57.40) | 60.320 | 40.010 |
| Contralateral breast | |||||||||
| Maximum dose (Gy) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 61.000 | 2.20 (0.19–10.30) | 10.001 | 20.001 | 0.12 (0.00–0.82) | 40.125 | 50.125 |
| Ipsilateral lung | |||||||||
| Mean dose (Gy) | 0.61 (0.08–1.28) | 0.81 (0.20–1.44) | 40.003 | 3.07 (0.39–6.06) | 10.001 | 20.001 | 0.84 (0.00–1.90) | 50.311 | 60.765 |
| V5Gy (%) | 3.50% (0.00–10.00) | 4.90% (0.00–10.00) | 40.007 | 18.40% (0.00–47.00) | 10.002 | 20.002 | 5.30% (0.10–12.40) | 50.278 | 60.906 |
| V10Gy (%) | 1.30% (0.00–5.00) | 2.10% (0.00–6.00) | 40.004 | 8.80% (0.00–17.00) | 10.002 | 20.002 | 2.90% (0.00–7.60) | 50.102 | 60.322 |
| V20Gy (%) | 0.10% (0.00–1.00) | 0.20% (0.00–1.00) | 60.156 | 3.50% (0.00–9.00) | 10.004 | 20.004 | 1.40% (0.00–4.20) | 30.020 | 50.105 |
| Contralateral lung | |||||||||
| Mean dose (Gy) | 0.02 (0.00–0.16) | 0.01 (0.00–0.13) | 40.500 | 0.13 (0.04–0.40) | 10.001 | 20.001 | 0.01 (0.00–0.07) | 50.875 | 60.875 |
| Heart | |||||||||
| Maximum dose (Gy) | 3.20 (0.00–16.10) | 2.90 (0.00–14.00) | 60.438 | 9.40 (0.78–37.00) | 20.01 | 30.01 | 6.00 (0.00–31.65) | 40.156 | 50.281 |
| Breast skin | |||||||||
| V90 (%) | 4.00% (0.00–11.00) | 3.70% (0.00–12.00) | 50.320 | 7.60% (1.50–22.50) | 30.005 | 40.005 | 11.50% (2.40–21.10) | 10.001 | 20.002 |
| V75 (%) | 14.50% (4.00–29.00) | 15.50% (6.00–35.00) | 60.278 | 22.70% (10.60–52.20) | 10.001 | 20.001 | 18.9% (10.00–38.20) | 30.001 | 40.002 |
| V50 (%) | 26.10% (17.00–48.00) | 30.80% (21.00–57.00) | 30.001 | 40.20% (27.90–73.80) | 10.001 | 20.001 | 27.80% (17.80–52.40) | 60.147 | 50.010 |
| V30 (%) | 37.00% (23.00–64.00) | 42.00% (31.00–70.00) | 30.001 | 52.60% (37.30–86.00) | 10.001 | 20.001 | 39.80% (28.10–59.30) | 60.067 | 50.064 |
| V10 (%) | 47.80% (31.00–77.00) | 52.90% (40.00–80.00) | 30.001 | 69.50% (47.80–92.20) | 10.001 | 20.001 | 47.30% (32.60–67.60) | 60.898 | 50.003 |
3DCRT, three-dimensional conformal photon radiotherapy; PSPB, passive scattering proton beam; TANG_EN, TANGENT_ENFACE; TANG_PA, TANGENT_PAIR.
np≤10.008, 20.010, 30.0125, 40.0167, 50.025, 60.050; the superscript is the rank of p-value. The italicised p-values are statistically significant.
a
Comparison of TANG_EN to TANG_PA.
b
Comparison of 3DCRT to TANG_EN.
c
Comparison of 3DCRT to TANG_PA.
d
Comparison of PSPB to TANG_EN.
e
Comparison of PSPB to TANG_PA.